GlassScriptPhysician profile
Kevin C Harned
NPI 1457444853
$1,652.54
in general payments reported to CMS, 2019-2025
21 companies · $276 in 2025
The $276 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $156 · 2021: $204 · 2022: $418 · 2023: $447 · 2024: $150 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737 · Travel and Lodging: $113 · Education: $23.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.47 |
| Travel and Lodging | $113.34 |
| Education | $23.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $456.61 | 2020-2023 | Farxiga |
| Amgen INC. | $153.41 | 2022-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $152.63 | 2021-2025 | Jynarque, Voyxact |
| Horizon Therapeutics Plc | $141.35 | 2020-2023 | Krystexxa |
| Nxstage Medical, INC. | $113.34 | 2023 | Nxstage System One |
| Ani Pharmaceuticals, INC. | $87.81 | 2022-2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $82.49 | 2024-2025 | Tarpeyo |
| Baxter Healthcare | $72.27 | 2022 | |
| Akebia Therapeutics INC | $62.65 | 2022-2023 | Auryxia |
| Travere Therapeutics, INC. | $59.95 | 2024-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $38.38 | 2020 | |
| Aurinia Pharma U.S., INC. | $36.84 | 2023-2025 | Lupkynis |
| Opko Pharmaceuticals, LLC | $34.20 | 2020 | |
| Apellis Pharmaceuticals, INC. | $26.41 | 2025 | Empaveli |
| Renalytix Ai, INC. | $24.30 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $22.15 | 2023 | Velphoro, Korsuva |
| Vifor Pharma, INC. | $19.32 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.17 | 2023 | Jynarque |
| Vantive US Healthcare LLC | $18.35 | 2025 | Renal - Acute |
| Glaxosmithkline, LLC. | $16.56 | 2023 | Jesduvroq |
| Boston Scientific Corporation | $14.35 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Harned listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.